More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.0 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 637.2M
Share based compensation 100.3M
Gain on sale of non-current investments
Other
Movement in deferred taxes -198.2M
Equity in earnings of equity method investees 2.2M
Loss/(gain) on sale of product rights -14.7M
Changes in operating assets and liabilities:
Increase in accounts receivable -211.4M
Increase in sales deduction accrual 97.6M
Increase in inventory -63.2M
Increase in prepayments and other assets 37.2M
Decrease in accounts payable and other liabilities 109.2M
Net cash provided by operating activities 2.34B
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash -32M
Purchases of subsidiary undertakings, net of cash acquired -5.55B
Purchases of non-current investments -9.5M
Purchases of property, plant and equipment ("PP&E") -114.7M
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 18.7M
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -5.62B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 3.76B
Repayment of debt acquired with ABH -3.11B
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 32.4M
Proceeds from exercise of options 16.6M
Payment of dividend -134.4M
Payments to acquire shares by ESOT
Net cash used in financing activities 439M
Net (decrease)/increase in cash and cash equivalents -2.85B
Effect of foreign exchange rate changes on cash and cash equivalents -3M
Cash and cash equivalents at beginning of period 2.98B
Cash and cash equivalents at end of period 135.5M
Supplemental information associated with continuing operations:
Interest paid -20M
Income taxes paid -145.9M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment